Abstract |
Ninety-four patients with early Parkinson's disease were investigated in a double-blind, placebo-controlled evaluation of MK-458 [ hydroxypropyl methylcellulose/ lactose matrix (HPMC)], a sustained release formulation of a novel naphthoxazine compound with selective D-2 dopamine receptor agonism. Patients were previously untreated with dopaminergic drugs. Efficacy was assessed by clinical rating scales and by patient self-evaluation. MK-458 (HPMC) caused a significant decrease in most parkinsonian symptoms. Though disability rating scores were lowered by the drug, the scores did not differ significantly from placebo. However, statistically significant improvement occurred with MK-458 (HPMC) on both the physician and the patient global assessments. Adverse reactions such as nausea and vomiting, sedation, confusion, and hallucinations occurred more with MK-458 (HPMC) than with placebo. MK-458 (HPMC) possesses antiparkinsonian efficacy in early Parkinson's disease; however, side-effects are frequently associated with its use. Selective D-2 receptor agonists, such as MK-458 (HPMC), may not be the ideal treatment as monotherapy for Parkinson's disease.
|
Authors | W C Koller, G A Block, J E Ahlskog, S Ahrens, J M Cedarbaum, G Cyhan, C G Goetz, P A LeWitt, C Liss, L McLean |
Journal | Clinical neuropharmacology
(Clin Neuropharmacol)
Vol. 14
Issue 4
Pg. 322-9
(Aug 1991)
ISSN: 0362-5664 [Print] United States |
PMID | 1913699
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Delayed-Action Preparations
- Oxazines
- Methylcellulose
- MK 458
- Lactose
|
Topics |
- Aged
- Delayed-Action Preparations
- Double-Blind Method
- Female
- Humans
- Lactose
(analogs & derivatives, therapeutic use)
- Male
- Methylcellulose
(analogs & derivatives, therapeutic use)
- Middle Aged
- Oxazines
- Parkinson Disease
(drug therapy)
|